- Home
- DXLG vs NSPR Comparison
DXLG vs NSPR Comparison
Compare DXLG & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- NSPR
- Stock Information
- Founded
- DXLG 1976
- NSPR 2005
- Country
- DXLG United States
- NSPR United States
- Employees
- DXLG N/A
- NSPR N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- NSPR Medical/Dental Instruments
- Sector
- DXLG Consumer Discretionary
- NSPR Health Care
- Exchange
- DXLG Nasdaq
- NSPR Nasdaq
- Market Cap
- DXLG 64.0M
- NSPR 75.1M
- IPO Year
- DXLG 1987
- NSPR N/A
- Fundamental
- Price
- DXLG $1.15
- NSPR $2.26
- Analyst Decision
- DXLG Strong Buy
- NSPR Strong Buy
- Analyst Count
- DXLG 1
- NSPR 2
- Target Price
- DXLG $2.50
- NSPR $4.50
- AVG Volume (30 Days)
- DXLG 632.5K
- NSPR 356.9K
- Earning Date
- DXLG 05-29-2025
- NSPR 08-05-2025
- Dividend Yield
- DXLG N/A
- NSPR N/A
- EPS Growth
- DXLG N/A
- NSPR N/A
- EPS
- DXLG N/A
- NSPR N/A
- Revenue
- DXLG $457,059,000.00
- NSPR $7,027,000.00
- Revenue This Year
- DXLG N/A
- NSPR $4.85
- Revenue Next Year
- DXLG $3.56
- NSPR $113.47
- P/E Ratio
- DXLG N/A
- NSPR N/A
- Revenue Growth
- DXLG N/A
- NSPR 8.49
- 52 Week Low
- DXLG $0.90
- NSPR $1.99
- 52 Week High
- DXLG $3.93
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- DXLG 49.13
- NSPR 34.73
- Support Level
- DXLG $0.98
- NSPR $1.99
- Resistance Level
- DXLG $1.09
- NSPR $2.59
- Average True Range (ATR)
- DXLG 0.07
- NSPR 0.14
- MACD
- DXLG -0.00
- NSPR -0.02
- Stochastic Oscillator
- DXLG 36.40
- NSPR 23.50
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.